Trial status March 2017

In Africa

The aim of the EBL2002 trial in Africa is to test the vaccine in a total of 1,188 subjects including healthy adults and population groups including the elderly, HIV-infected adults, adolescents and children. So far, 1688 participants have been screened and 858 have been randomized across Cohort 1(healthy adults), Cohort 2A (HIV-infected individuals) and Cohort 2B (healthy adolescents), of which 613 have received the boost vaccination.

In Europe

The EBL2001 trial in Europe (UK, France) aims to vaccinate a total of 630 subjects (healthy adults). So far, 423 study participants in Europe have been randomized (143 were randomized in reporting year 1 and 280 in reporting year 2), of which 290 have received the boost vaccination.

From a scientific perspective


Thanks to the finalisation of Cohort 1, the first results in EBOVAC2 on the immune response to the vaccine were obtained by the Oxford Vaccine Group (UOXF) in a subcohort of 30 participants in the UK.  During the last 12 months, UOXF has been characterising the B cell response to Ad26.ZEBOV/MVA.BN.Filo and has shown strong plasma cell responses and also identified their phenotypes. The group has also begun preliminary analysis of the antibody VH-gene response post Ad prime and MVA boost and initial isolation of monoclonal antibodies has been achieved by the Townsend group.

News

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018. For more information

  • 02 January 2018

    The 4th edition of our EBOVAC2 newlsetter was released on the 21st of December 2017.

  • 27 October 2017

    The 3rd EBOVAC2 Newsletter is now available here. Our October 2017 issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz site.

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research